The Heart of the Matter: Behind the Renewed Interest in Cardiovascular Disease

10/12/23 • 24 min

A conversation on the rising trends in the cardiology space

Cardiology has historically been a cornerstone of large pharmaceutical portfolios. The late 2000s and 2010s saw many pharmaceutical companies and investors abandon or severely deprioritize cardiology research and development in favor of oncology, immunology, and neurology.

During this episode of The Life Science Report, Dr. Pete Bak and Christian Thienel of Back Bay Life Science Advisors discuss the major players in the industry and novel approaches to future cardiology applications.

Episode topics include:

Why pharma’s interest in specialty-like approaches has shifted towards cardiology
The promise of “advanced modalities” and gene therapies, such as antisense oligonucleotides (ASOs) and small interfering RNA (siRNA)
How these newer treatments stack up against traditional small molecule orals, like statins
Clinical stage pipeline analysis across cardiology and visible trends on the horizon

This is the 20th episode of Back Bay’s podcast, covering all facets of healthcare development and transactions. For questions, be in touch: www.bblsa.com

A conversation on the rising trends in the cardiology space

Episode topics include:

Why pharma’s interest in specialty-like approaches has shifted towards cardiology
The promise of “advanced modalities” and gene therapies, such as antisense oligonucleotides (ASOs) and small interfering RNA (siRNA)
How these newer treatments stack up against traditional small molecule orals, like statins
Clinical stage pipeline analysis across cardiology and visible trends on the horizon

This is the 20th episode of Back Bay’s podcast, covering all facets of healthcare development and transactions. For questions, be in touch: www.bblsa.com

Previous Episode

The Transactional Landscape Of ADCs: The Powerhouse of Antibody Drug Conjugates

In this episode, Dr. Peter Bak is joined by Trent Gordon and Dr. Mavra Nasir as they discuss their Bioprocess Online article published earlier this year, “The Transactional Landscape of ADCs: A Payday for Payloads.” This conversation explores the dynamics and data within the emerging ADC field, including:

Background information on the class of therapeutics known as ADCs, which have been on the market since 2000
The number of headlines around ADCs lately, especially the standing ovation the data from Enhertu received at ASCO in 2022, making waves in breast cancer treatment
Deal structures and the BD side of ADCs, and their extended revenue generation potential
Where the field is headed, in terms of clinical, BD and commercial standpoints

Read and connect with our authors: The Transactional Landscape Of ADCs: A Payday for Payloads

Next Episode

The Current and Future Landscape of Healthcare IPO Markets

With the DNB//Back Bay Partnership for Healthcare

In the current markets, Healthcare continues to rally as the second-largest industry behind technology in the stock market, and in the US markets there’s been roughly $2.5B raised from an IPO standpoint YTD. In Europe, the markets have been more challenging, with IPOs for five companies going public this year, including Schott Pharma, Germany’s largest IPO earlier this year.

In the first podcast episode with the DNB//Back Bay Partnership for Healthcare, Jonathan Gertler, Back Bay CEO and Managing Partner is joined by Jim Cirenza, Head of Fixed Income and Equities at DNB, Kristoffer Braaten, Director and Head of Equity Capital Markets at DNB, and Vasilios Kofitsas, Partner and Managing Director of Investment Banking at Back Bay Life Science Advisors, to discuss the current landscape of IPO and capital markets, optimal preparation strategies for companies hoping to go public and why it ultimately matters who you spend your time with.

Topics in this episode include:

Dynamics leading to the current IPO market and capital markets landscape
The state of private and partnering markets and the renewed power of partnerships
Crucial roles of private investments, VC and other “mezzanine investors” for public emergence licensing
The importance of optimal prep and aftermarket support, and why spending good time in the preparation phase with both research and individual investor meetings is a key success factor, regardless of where companies are planning to list
The ever-important lesson of starting early